Heterologous priming with the ChAdOx1 nCoV-19 vector vaccine followed by boosting with
a messenger RNA vaccine (BNT162b2 or mRNA-1273) is currently recommended in …

Comparative analyses of the immunogenicity and reactogenicity of homologous and
heterologous SARS-CoV-2 vaccine-regimens will inform optimized vaccine strategies. Here we …

Background The NVX-CoV2373-vaccine has recently been licensed, although knowledge on
vaccine-induced humoral and cellular immunity towards the parental strain and variants of …

Abstract Knowledge is limited as to how prior SARS-CoV-2 infection influences cellular and
humoral immunity after booster-vaccination with bivalent BA.4/5-adapted mRNA-vaccines, …

Abstract Knowledge on immunogenicity of the bivalent Omicron BA.4/5 vaccine in dialysis
patients and the effect of a previous infection is limited. Therefore, vaccine-induced humoral …

The NVX-CoV2373-vaccine has recently been licensed, although data on vaccine-induced
humoral and cellular immunity towards the parental strain and variants of concern (VOCs) in …

Head-to-head analyses of immunogenicity and reactogenicity between the authorized
homologous vaccine-regimens and heterologous combinations thereof are currently limited. …

… The authors thank Candida Guckelmus and Rebecca Urschel for excellent technical assistance,
and Dr. Christina Baum and the team of the occupational health care center at Saarland …

… The authors thank Candida Guckelmus and Rebecca Urschel for excellent technical assistance,
and Susanne Brehmer, Inna Vallar, Fabio Lizzi and the team of the Saarland University …

… The authors thank Candida Guckelmus and Rebecca Urschel for excellent technical
assistance. The authors also thank all participants in this study who contributed to the gain in …